https://adzebiotech.com/ 2025-10-27T16:04:32+00:00 https://adzebiotech.com/news/ 2025-09-24T05:41:00+00:00 https://adzebiotech.com/home-copy/ 2026-05-05T16:50:19+00:00 https://adzebiotech.com/hepatocellular-carcinoma-hcc/ 2026-01-12T17:30:23+00:00 https://adzebiotech.com/triple-negative-breast-cancer/ 2026-01-12T17:28:34+00:00 https://adzebiotech.com/melanoma-treatment-in-australia/ 2026-01-09T18:05:57+00:00 https://adzebiotech.com/pipeline/ 2026-01-23T15:29:11+00:00 https://adzebiotech.com/partnering/ 2023-02-07T16:26:33+00:00 https://adzebiotech.com/contact/ 2024-12-18T10:30:43+00:00 https://adzebiotech.com/science/ 2026-01-23T15:31:44+00:00 https://adzebiotech.com/about/ 2025-10-27T18:16:49+00:00 https://adzebiotech.com/adze-biotechnology-and-kings-college-london-announce-clinical-collaboration-in-hard-to-treat-breast-cancer/ 2025-10-27T17:54:10+00:00 https://adzebiotech.com/adze-biotechnology-submits-bellberry-hrec-application-for-adze1-c-clinical-trial-in-australia/ 2025-10-27T17:47:41+00:00 https://adzebiotech.com/paola-grandi-joins-adze-biotechnology-to-lead-pre-clinical-and-translational-research-programs/ 2024-04-11T14:43:00+00:00 https://adzebiotech.com/adze-biotechnology-reports-us-patent-office-grants-patent-claiming-novel-recombinant-adenovirus/ 2024-04-11T14:32:37+00:00 https://adzebiotech.com/adze-biotechnology-announces-members-of-scientific-advisory-board/ 2024-04-11T14:17:41+00:00 https://adzebiotech.com/adze-biotechnology-completes-6-2-million-first-closing-of-series-a-financing/ 2023-03-20T17:16:50+00:00 https://adzebiotech.com/adze-biotechnology-granted-patent-for-its-proprietary-oncolytic-adenovirus-platform-copy/ 2023-02-10T17:24:01+00:00 https://adzebiotech.com/adze-biotechnology-granted-patent-for-its-proprietary-oncolytic-adenovirus-platform/ 2023-02-08T13:06:28+00:00 https://adzebiotech.com/elementor-hf/before-footer/ 2022-06-17T20:51:26+00:00